Table 3.

CCM efficacy results

	Before CCM Implantation	At Last Follow‐up	P Value
NYHA class	2.9 ± 0.4	2.1 ± 0.7	<0.0001
MLWHFQ score	50.2 ± 23.7	29.6 ± 22.8	<0.0001
LVEF, %	24.4 ± 8.1	30.9 ± 9.6	0.002
LVEDD, mm	66.6 ± 7.1	64.4 ± 6.5	0.087
LVESD, mm	59.2 ± 7.2	54.8 ± 7.3	0.012
LVEDV, mL	230.0 ± 49.2	207.8 ± 65.0	0.029
LVESV, mL	175.8 ± 46.1	147.2 ± 60.1	0.011
QRS duration, ms	108.9 ± 19.4	110.0 ± 22.0	0.663
NT‐proBNP, pg/mL	2882.7 ± 5456.6	2460.7 ± 7575.6	0.561
Cr, mg/dL	1.37 ± 0.83	1.32 ± 0.51	0.278
Paroxysmal AF events, %	5	15	0.163

Abbreviations: AF, atrial fibrillation; CCM, cardiac contractility modulation; Cr, creatinine; LVEDD, left ventricular end‐diastolic diameter; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; LVESD, left ventricular end‐systolic diameter; LVESV, left ventricular end‐systolic volume; MLWHFQ, Minnesota Living With Heart Failure Questionnaire; NT‐proBNP, N‐terminal pro brain natriuretic peptide; NYHA, New York Heart Association; SD, standard deviation.

Data are presented as mean ± SD unless otherwise noted.